Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer

NCT ID: NCT02361320

Last Updated: 2026-01-14

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 259 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-03-09
• Study Completion Date: 2026-06-27

Brief Summary

This trial studies how well computed tomography works in diagnosing patients with pancreatic or hepatobiliary cancer. Computed tomography may help researchers predict how patients with pancreatic or hepatobiliary cancer may respond to chemotherapy.

Detailed Description

PRIMARY OBJECTIVES:

I. To prospectively validate our pilot data that indicate that pre-therapy computed tomography-based (CT) mass transport properties correlate with overall survival.

II. To prospectively validate our pilot data that indicate that local control of pancreatic and hepatobiliary tumors correlate with changes in computed tomography-based mass transport properties of the tumors after cytotoxic therapies.

OUTLINE:

Patients undergo CT scan at baseline and after 4 to 6 cycles of fluorouracil/irinotecan/leucovorin calcium/oxaliplatin, or after 4 infusions of gemcitabine/nab-paclitaxel (or other gemcitabine-based regimens), or 6 to 12 weeks after radiotherapy for hepatobiliary cancers. Patients may undergo optional magnetic resonance imaging (MRI) scans prior to therapy, after two weeks of therapy, and at the time of the first restaging CT scan.

Conditions

Pancreatic Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Computed Tomography Scans (CT)

Participants to receive 2 computed tomography (CT) scans that are part of their regular cancer care. One (1) scan performed before the start of chemotherapy, and the other at first restaging visit with oncologist. Participant to complete the MD Anderson Symptom Inventory for Gastrointestinal cancer (MDASI-GI) questionnaire at baseline visit, and follow up visit.

Group Type: EXPERIMENTAL

Computed Tomography (CT)

Intervention Type: PROCEDURE

Participants to receive 2 CT scans. One scan performed before the start of chemotherapy, and the other at first restaging visit with oncologist.

Questionnaire

Intervention Type: BEHAVIORAL

Participant to complete the MD Anderson Symptom Inventory for Gastrointestinal cancer (MDASI-GI) questionnaire at baseline visit, and follow up visit. Questionnaires should take about 10 minutes to complete.

Interventions

Computed Tomography (CT)

Participants to receive 2 CT scans. One scan performed before the start of chemotherapy, and the other at first restaging visit with oncologist.

Intervention Type: PROCEDURE

Questionnaire

Participant to complete the MD Anderson Symptom Inventory for Gastrointestinal cancer (MDASI-GI) questionnaire at baseline visit, and follow up visit. Questionnaires should take about 10 minutes to complete.

Intervention Type: BEHAVIORAL

Other Intervention Names

CT; Survey

Eligibility Criteria

Inclusion Criteria

• PANCREATIC CANCER: Histologically confirmed adenocarcinoma of the pancreas
• PANCREATIC CANCER: Non-distant metastatic pancreatic cancer that is either

• Unresectable locally advanced disease, defined as primary tumor that involves > 180 degrees of the superior mesenteric artery, celiac axis or any of its branches on CT or MRI, primary tumor that occludes the superior mesenteric vein or portal vein, aorta or inferior vena cava invasion, or superior mesenteric vein invasion below the transverse mesocolon
• Borderline resectable disease, defined as primary tumor that involves =< 180 degrees of the superior mesenteric artery, celiac axis or any of its branches on CT or MRI, primary tumor that involves the superior mesenteric vein causing vein deformity or segmental venous occlusion with a patent vessel above and below suitable for reconstruction, or primary tumor that abuts or encases (>= 50% of the vessel circumference) a short segment of the common hepatic artery (typically at the gastroduodenal artery origin)
• PANCREATIC CANCER: Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
• PANCREATIC CANCER: Women of childbearing potential (those who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 consecutive months) must agree to practice adequate contraception and to refrain from breast feeding
• PANCREATIC CANCER: Patient who has been recommended chemotherapy treatment for pancreatic cancer
• PANCREATIC CANCER: Signed study-specific consent form
• HEPATOBILIARY CANCER: Diagnosis of

• Hepatocellular carcinoma: This may be diagnosed in the following ways:

• Pathologically (histologically or cytologically) proven diagnosis of hepatocellular carcinoma (HCC)
• At least one solid liver lesion with arterial enhancement and washout on a delayed phase of a multi-phasic CT or MRI in the setting of cirrhosis or chronic hepatitis B or C without cirrhosis
• Intrahepatic cholangiocarcinoma: Pathologically (histologically or cytologically) proven diagnosis of intrahepatic cholangiocarcinoma
• HEPATOBILIARY CANCER: Patients may have single or multinodular tumors
• HEPATOBILIARY CANCER: ECOG PS 0-1
• HEPATOBILIARY CANCER: Women of childbearing potential (those who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 consecutive months) must agree to practice adequate contraception
• HEPATOBILIARY CANCER: Prior history of surgical resection, chemotherapy, transarterial chemoembolization (TACE), and/or radiofrequency ablation are allowed
• HEPATOBILIARY CANCER: Patients may be enrolled if:

• The patient is dispositioned to receive definitive radiotherapy
• The patient has received definitive radiotherapy within the past two years and has liver protocol CT or MRI scans before radiotherapy and at first restaging after radiotherapy
• HEPATOBILIARY CANCER: Signed study-specific consent form

Exclusion Criteria

• Presence of distant metastasis
• Patients whose tumors are defined as resectable
• Unstable angina or New York Heart Association grade II or greater congestive heart failure
• Evidence of fever or acute infection (chronic infection such as hepatitis virus is acceptable)
• Coexisting medical condition that would preclude chemotherapy, radiotherapy, or iodine-based contrast enhanced CT scan
• Pregnant women with a positive pregnancy test
• Inability to comply with study and/or follow-up procedures
• Patients with an active second malignancy with the exception of non-melanoma skin cancer

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

M.D. Anderson Cancer Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Eugene Koay

Role: PRINCIPAL_INVESTIGATOR

M.D. Anderson Cancer Center

Locations

M D Anderson Cancer Center

Houston, Texas, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Eugene Koay

Role: CONTACT

ekoay@mdanderson.org

713-563-2300

Facility Contacts

Eugene J. Koay

Role: primary

713-563-2300

Related Links

http://www.mdanderson.org

MD Anderson Cancer Center Website

Other Identifiers

NCI-2018-02642

Identifier Type: REGISTRY

Identifier Source: secondary_id

PA14-0319

Identifier Type: OTHER

Identifier Source: secondary_id

PA14-0319

Identifier Type: -

Identifier Source: org_study_id